CClinicalTrials.gg
CompletedNCT05736237GENODDUpdated Aug 2, 2024

Identification and Verification of Candidate Genes Responsible for Optic Disc Drusen Development

An observational study in Optic Disk Drusen, sponsored by Copenhagen University Hospital at Herlev. Completed at 1 site in Denmark. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2024-08-02.

Sponsored by Copenhagen University Hospital at Herlev · Observational

Study type
Observational
Model
Family-based
Time perspective
Cross-sectional
Enrollment
20
Ages
18 Years to 100 Years
Sex
All
01

Study summary

The goal of this observational study is to learn about the genetic background for the development of optic disc drusen. The main question is:

  • Can one or more candidate genes be found?

Participants will have a blood sample taken and answer a questionnaire.

Read the detailed description

The study is an international collaboration between University of Utah, University of Sydney, University of Valladolid, and University of Copenhagen. Patients with Optic disc drusen from 15 known optic disc drusen-families from different countries (USA, Australia, Spain and Denmark) are participating in this study.

Blood samples are drawn from each patient and their affected and unaffected family members, and DNA will be extracted. The investigators will do an Optical coherence tomography-scan (according to ODDS Consortium guidelines), and the participant will be asked to fill out the Visual Function Questionnaire (VFQ-25) including four additional questions about optic disc drusen.

The etiology of optic disc drusen will be analyzed with a Whole Exome Sequencing (WES), with the use of Next Generation Sequencing (NGS). Prior to WES, all participants will receive genetic counseling by a consultant to ensure awareness of possible secondary genetic findings.

02

Conditions studied

  • Optic Disk Drusen

Keywords

  • Optic disc drusen
  • Genetics
03

In context

Lead sponsor

Copenhagen University Hospital at Herlev is the lead sponsor of 76 studies on the registry; 10 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Families with ODD

Inclusion criteria

  • Adult patients over the age of 18, who are capable of giving consent
  • Diagnosis of optic disc drusen and a minimum of 3 optic disc drusen-affected family members

Exclusion criteria

Exclusion Criteria:

  • Less than 3 affected family members
  • Under the age of 18 or mentally disabled
05

Study design

Observational model
Family-based
Time perspective
Cross-sectional
Enrollment
20 participants (actual)
Patient registry
No

Groups and cohorts

  • Families with optic disc drusen

    Genetic: Whole exome sequencing

Interventions

  • GeneticWhole exome sequencing

    With Next Generation Sequenzing

06

What researchers measure

Primary outcomes

  1. Candidate gene

    Genetics variants shared by the families will be compared with findings in the remaining families and identical genes will undergo further analysis.

    Time frame: 2023-2024

07

Study locations

1 site
  • Department of Ophthalmology
    Glostrup, 2600, Denmark
08

References and documents

Individual participant data

Plan to share: No — Data will only be shared with the project responsible unit

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 2, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05736237
Lead sponsor
Copenhagen University Hospital at Herlev
Responsible party
Alvilda Steensberg (Principal Investigator, Rigshospitalet, Denmark) — Principal investigator
First posted
Feb 21, 2023
Start date
May 1, 2023
Primary completion
May 31, 2024
Completion
May 31, 2024
Last update
Aug 2, 2024

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion